Xceleron and Covance enter co-promotional agreement
Xceleron announced a cooperation agreement with Covance in which both companies will make available each others drug development services to their customers. In addition Xceleron and Covance will carry out joint projects on behalf of sponsors and to further the development of new applications.
Xceleron CEO, Professor Colin Garner commented that "this is a strategically important deal for Xceleron. It demonstrates how quickly our technology has moved from being seen as novel and at the edges of drug development to its acceptance as a mainstream part of the drug development process. Covance is a great partner to have and this agreement will add global marketing power to our business; we look forward to working closely with them".
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.